Abstract:
본 발명은 신규한 데커시놀 유도체(decursinol derivative), 그 제조방법 및 이를 유효성분으로 포함하는 약학 조성물에 관한 것이다. 상기 신규한 데커시놀 유도체 화합물은 뇌허혈에 의해 유발되는 신경세포의 손상을 효과적으로 예방하고, 아교세포 활성 억제능이 있으며, 뇌허혈에 의한 신경세포사를 억제할 수 있고, 허혈에 의해 유발되는 유발되는 NF-κB의 발현을 효과적으로 저해할 수 있으며, LPS(lipopolysaccharide)에 의해 유발되는 면역세포 내의 NO 분비량을 효과적으로 억제할 수 있어서, 상기 화합물은 다양한 질병의 치료 용도에 사용될 수 있고, 일 예로 약학 조성물 또는 질병의 치료, 개선 또는 완화용 조성물의 유효성분으로 사용될 수 있다.
Abstract:
PURPOSE: A composition containing a novel decursinol derivative for anti-inflammation is provided to ensure low cytotoxicity and excellent NO suppression and to prevent or treat inflammatory diseases. CONSTITUTION: A composition for anti-inflammation contains decursinol derivative of chemical formula 1 or pharmaceutically acceptable salt thereof as an active ingredient. A composition for NF-kappa B suppression contains the decursinol derivative or pharmaceutically acceptable salt thereof as an active ingredient. A composition for preventing or treating multiple myeloma contains the decursinol derivative or pharmaceutically acceptable salt thereof as an active ingredient.
Abstract:
본 발명은 흰색 감국 추출물을 유효성분으로 포함하는 허혈성 뇌혈관 질환 예방 또는 개선용 조성물에 관한 것으로, 보다 상세하게는 뇌허혈에 민감하다고 알려져 있는 뇌 해마조직 CA1 영역의 신경 손상을 효과적으로 예방할 뿐만 아니라, 인체에 무해한 흰색 감국 추출물을 유효성분으로 포함하는 허혈성 뇌혈관 질환 예방 또는 개선용 조성물에 관한 것이다. 흰색 감국, 허혈성 뇌혈관 질환, 치매, 알츠하이머
Abstract:
A composition for preventing or treating brain ischemia diseases, which contains white Chrysanthemum indicum Var. albescens as an active ingredient is provided to prevent nerve injury of CA1 area of brain hippocampus. A composition for preventing and treating brain ischemia diseases comprises 0.001-99.99 weight% of Chrysanthemum indicum var. albescens extract as an active ingredient. The brain ischemia diseases are cerebral infarction, cerebral hemorrhage, subarachnoid hemorrhage and white matter. The Chrysanthemum indicum var. albescens extract is isolated with 30-80% of alcohol solution of 1-5 carbon atoms. The composition further comprises a carrier, excipient, and diluents. The composition is used in a form of powder, granule, tablet, suspension, emulsion or syrup.
Abstract:
PURPOSE: A pharmaceutical composition containing Melissa officinalis extract for promoting neuroblast differentiation due to aging is provided. CONSTITUTION: A pharmaceutical composition for promoting differentiation and proliferation of neuroblast contains 0.01-50 wt% Melissa officinalis extract as an active ingredient, isolated from Melissa officinalis using water, low alcohol of C-C4, or mixture solvent thereof. The neurobalst is hippocampus, dentate gyrus, and subgranular zone-derived nerve stem cells. A functional food for promoting differentiation and proliferation of neurobalst contains the Melissa officinalis extract as an active ingredient.
Abstract:
PURPOSE: A pharmaceutical composition containing escitalopram is provided to prevent neural cell damage in a CA1 area and to prevent or treat ischemic brain diseases. CONSTITUTION: A pharmaceutical composition for preventing or treating ischemic a brain disease contains escitalopram. Ischemic brain disease is thrombosis, embolism, transient ischemic attack, cerebral infarction, cerebral hemorrhage, subarachnoid hemorrhage, white matter dyslipidemia, or lacune. The administering of escitalopram prevents or treats ischemic brain diseases. A pharmaceutical composition for preventing or treating brain disease contains escitalopram and a pharmaceologically acceptable carrier or excipient. The pharmaceutically acceptable carrier or excipient is water, dextrin, or a saline solution. The composition is used in the form of plasters, granules, lotions, powders, syrups, liquids and solutions, aerosols, ointments, fluid extract, emulsion, suspensions, infusions, tablets, injections, capsules, or pills.
Abstract:
A mask pack is provided to inhibit the damage induced by UVB by increasing anti-oxidase such as manganese superoxide dismutase and glutathione peroxidase without causing any skin irritation. A mask pack for improving skin damage caused by UVB comprises 0.1-0.4 parts by weight of coenzyme Q10, 7.0-12.0 parts by weight of glycerin, 0.05-0.3 parts by weight of allantoin, 85-95 parts by weight of purified water, 0.04-0.08 parts by weight of carbomer, and 0.05-0.3 parts by weight of triethanolamine. The pack is a sheet type or a patch type.
Abstract:
본 발명은 신규한 데커시놀 유도체(decursinol derivative), 그 제조방법 및 이를 유효성분으로 포함하는 약학 조성물에 관한 것이다. 상기 신규한 데커시놀 유도체는 신경세포 보호능 및 아교세포 활성 억제능이 있을 뿐만 아니라 NF-κB 활성 저해능이 있으므로, 이를 유효성분으로 포함하는 상기 약학 조성물은 허혈성 뇌혈관 질환의 치료 또는 예방용 조성물로 사용될 수 있다.